Serotonin regulation of mitochondria in kidney diseases

IF 9.1 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pharmacological research Pub Date : 2024-03-22 DOI:10.1016/j.phrs.2024.107154
Kevin Hurtado , Natalie E. Scholpa , Jennifer G. Schnellmann , Rick G. Schnellmann
{"title":"Serotonin regulation of mitochondria in kidney diseases","authors":"Kevin Hurtado ,&nbsp;Natalie E. Scholpa ,&nbsp;Jennifer G. Schnellmann ,&nbsp;Rick G. Schnellmann","doi":"10.1016/j.phrs.2024.107154","DOIUrl":null,"url":null,"abstract":"<div><p>Serotonin, while conventionally recognized as a neurotransmitter in the CNS, has recently gained attention for its role in the kidney. Specifically, serotonin is not only synthesized in the kidney, but it also regulates glomerular function, vascular resistance, and mitochondrial homeostasis. Because of serotonin’s importance to mitochondrial health, this review is focused on the role of serotonin and its receptors in mitochondrial function in the context of acute kidney injury, chronic kidney disease, and diabetic kidney disease, all of which are characterized by mitochondrial dysfunction and none of which has approved pharmacological treatments. Evidence indicates that activation of certain serotonin receptors can stimulate mitochondrial biogenesis (MB) and restore mitochondrial homeostasis, resulting in improved renal function. Serotonin receptor agonists that induce MB are therefore of interest as potential therapeutic strategies for renal injury and disease.</p></div><div><h3>Significance statement</h3><p>Mitochondrial dysfunction is associated with many human renal diseases such as acute kidney injury, chronic kidney disease, and diabetic kidney disease, which are associated with increased morbidity and mortality. Unfortunately, none of these pathologies has an FDA-approved pharmacological intervention, underscoring the urgency of identifying new therapeutics for such disorders. Studies show that induction of mitochondrial biogenesis via serotonin (5-hydroxytryptamine, 5-HT) receptors reduces kidney injury markers, restores mitochondrial and renal function after kidney injury, and decreases mortality, suggesting that targeting 5-HT receptors may be a promising therapeutic avenue for mitochondrial dysfunction in kidney diseases. While numerous reviews describe the importance of mitochondria and mitochondrial quality control mechanisms in kidney disease, the relevance of 5-HT receptor-mediated mitochondrial metabolic modulation in the kidney has yet to be thoroughly explored.</p></div>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":"203 ","pages":"Article 107154"},"PeriodicalIF":9.1000,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1043661824000987/pdfft?md5=afe65a6acb1b9cd1065893131a85832b&pid=1-s2.0-S1043661824000987-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043661824000987","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Serotonin, while conventionally recognized as a neurotransmitter in the CNS, has recently gained attention for its role in the kidney. Specifically, serotonin is not only synthesized in the kidney, but it also regulates glomerular function, vascular resistance, and mitochondrial homeostasis. Because of serotonin’s importance to mitochondrial health, this review is focused on the role of serotonin and its receptors in mitochondrial function in the context of acute kidney injury, chronic kidney disease, and diabetic kidney disease, all of which are characterized by mitochondrial dysfunction and none of which has approved pharmacological treatments. Evidence indicates that activation of certain serotonin receptors can stimulate mitochondrial biogenesis (MB) and restore mitochondrial homeostasis, resulting in improved renal function. Serotonin receptor agonists that induce MB are therefore of interest as potential therapeutic strategies for renal injury and disease.

Significance statement

Mitochondrial dysfunction is associated with many human renal diseases such as acute kidney injury, chronic kidney disease, and diabetic kidney disease, which are associated with increased morbidity and mortality. Unfortunately, none of these pathologies has an FDA-approved pharmacological intervention, underscoring the urgency of identifying new therapeutics for such disorders. Studies show that induction of mitochondrial biogenesis via serotonin (5-hydroxytryptamine, 5-HT) receptors reduces kidney injury markers, restores mitochondrial and renal function after kidney injury, and decreases mortality, suggesting that targeting 5-HT receptors may be a promising therapeutic avenue for mitochondrial dysfunction in kidney diseases. While numerous reviews describe the importance of mitochondria and mitochondrial quality control mechanisms in kidney disease, the relevance of 5-HT receptor-mediated mitochondrial metabolic modulation in the kidney has yet to be thoroughly explored.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血清素对肾脏疾病中线粒体的调节作用
血清素是中枢神经系统中的一种神经递质,但最近它在肾脏中的作用也引起了人们的关注。具体来说,血清素不仅能在肾脏中合成,还能调节肾小球功能、血管阻力和线粒体平衡。由于血清素对线粒体健康的重要性,本综述将重点讨论血清素及其受体在急性肾损伤、慢性肾病和糖尿病肾病的线粒体功能中的作用。有证据表明,激活某些羟色胺受体可刺激线粒体生物生成(MB),恢复线粒体平衡,从而改善肾功能。因此,诱导线粒体生物生成的血清素受体激动剂是治疗肾损伤和肾脏疾病的潜在疗法。遗憾的是,这些病症都没有获得美国食品及药物管理局批准的药物干预措施,这凸显了确定此类疾病新疗法的紧迫性。研究表明,通过血清素(5-羟色胺,5-HT)受体诱导线粒体生物生成可减少肾损伤标志物,恢复肾损伤后的线粒体和肾功能,并降低死亡率。虽然许多综述描述了线粒体和线粒体质量控制机制在肾脏疾病中的重要性,但 5-HT 受体介导的线粒体代谢调节在肾脏中的相关性仍有待深入探讨。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
相关文献
Review: Efficacy of preventative interventions for children and adolescents at clinical high risk of psychosis – a systematic review and meta-analysis of intervention studies
IF 6.8 3区 医学Child and Adolescent Mental HealthPub Date : 2024-12-17 DOI: 10.1111/camh.12755
Grace Frearson, Javier de Otazu Olivares, Ana Catalan, Claudia Aymerich, Gonzalo Salazar de Pablo
来源期刊
Pharmacological research
Pharmacological research 医学-药学
CiteScore
18.70
自引率
3.20%
发文量
491
审稿时长
8 days
期刊介绍: Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.
期刊最新文献
Multidimensional mechanisms of anxiety and depression in Parkinson’s disease: Integrating neuroimaging, neurocircuits, and molecular pathways Corrigendum to "CBX4 regulation of senescence and associated diseases: Molecular pathways and mechanisms" [Pharmacol. Res. 215 (2025) 107705]. Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis Alternative splicing: A key regulator in T cell response and cancer immunotherapy DIORS: Enhancing drug-target interaction prediction via structure and signature integrated-driven approach and discovering potential targeted molecules.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1